For the combination column it says the range is simply unknown, because concurrent use has not been systematically studied
While this area of research is still in its infancy, the implications for aging and longevity could be significant
Similarly, Ozempic is not licensed in the UK for weight management outside the context of diabetes, although a higher-dose formulation (Wegovy) has a specific licence for obesity treatment
Brief post-injection facial flushing The most consistent community feedback is a warmth and visible flush in the face, neck, and upper chest within 5-15 minutes of injection, fading by 30 minutes
(2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Aug 2018;14(2):299-303